通过慢病毒载体进行癌症和传染病的免疫接种。
Immunization delivered by lentiviral vectors for cancer and infectious diseases.
机构信息
Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA.
出版信息
Immunol Rev. 2011 Jan;239(1):45-61. doi: 10.1111/j.1600-065X.2010.00967.x.
Abstract
The increasing level of understanding of the lentivirus biology has been instrumental in shaping the design strategy of creating therapeutic lentiviral delivery vectors. As a result, lentiviral vectors have become one of the most powerful gene transfer vehicles. They are widely used for therapeutic purposes as well as in studies of basic biology, due to their unique characteristics. Lentiviral vectors have been successfully employed to mediate durable and efficient antigen expression and presentation in dendritic cells both in vitro and in vivo, leading to the activation of cellular immunity and humoral responses. This capability makes the lentiviral vector an ideal choice for immunizations that target a wide range of cancers and infectious diseases. Further advances into optimizing the vector system and understanding the relationship between the immune system and diseases pathogenesis will only augment the potential benefits and utility of lentiviral vaccines for human health.
摘要
对慢病毒生物学的理解水平不断提高，这对创造治疗性慢病毒传递载体的设计策略产生了重大影响。因此，慢病毒载体已成为最强大的基因转移载体之一。由于其独特的特性，它们被广泛用于治疗目的以及基础生物学研究。慢病毒载体已成功用于在体外和体内介导树突状细胞中持久和有效的抗原表达和呈递，从而激活细胞免疫和体液反应。这种能力使慢病毒载体成为针对广泛的癌症和传染病的免疫接种的理想选择。进一步优化载体系统并深入了解免疫系统与疾病发病机制之间的关系，将只会增加慢病毒疫苗对人类健康的潜在益处和实用性。
相似文献
1
Immunization delivered by lentiviral vectors for cancer and infectious diseases.通过慢病毒载体进行癌症和传染病的免疫接种。
Immunol Rev. 2011 Jan;239(1):45-61. doi: 10.1111/j.1600-065X.2010.00967.x.
2
Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo.用靶向MHC II类阳性细胞的慢病毒载体免疫小鼠是由于体内树突状细胞的优先转导。
PLoS One. 2014 Jul 24;9(7):e101644. doi: 10.1371/journal.pone.0101644. eCollection 2014.
3
From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.从病原体到药物：源自HIV-1的慢病毒载体作为基于树突状细胞的癌症免疫疗法的载体
J Gene Med. 2006 Jan;8(1):3-17. doi: 10.1002/jgm.846.
4
Lentiviral vectors for anti-tumor immunotherapy.用于抗肿瘤免疫治疗的慢病毒载体
Curr Gene Ther. 2008 Dec;8(6):438-48. doi: 10.2174/156652308786848058.
5
Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.评估一种表达猴免疫缺陷病毒gag的自失活慢病毒载体在体外和体内诱导特异性免疫反应的能力。
Viral Immunol. 2006 Winter;19(4):690-701. doi: 10.1089/vim.2006.19.690.
6
Toward integrase defective lentiviral vectors for genetic immunization.用于基因免疫的整合酶缺陷型慢病毒载体研究
Curr HIV Res. 2010 Jun;8(4):274-81. doi: 10.2174/157016210791208622.
7
Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.慢病毒载体在树突状细胞中表达肿瘤抗原作为一种免疫治疗策略。
Cancer Immunol Immunother. 2006 Aug;55(8):1011-6. doi: 10.1007/s00262-005-0095-5. Epub 2005 Nov 26.
8
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.用慢病毒载体转导的树突状细胞进行免疫可诱导强烈且持久的T细胞反应和治疗性免疫。
J Immunol. 2005 Mar 15;174(6):3808-17. doi: 10.4049/jimmunol.174.6.3808.
9
Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.慢病毒载体介导人抗原呈递细胞表达肿瘤相关表位。
Hum Gene Ther. 2004 Apr;15(4):393-404. doi: 10.1089/104303404322959542.
10
Viral vectors for gene transfer into antigen presenting cells.用于将基因导入抗原呈递细胞的病毒载体。
Curr Opin Mol Ther. 1999 Oct;1(5):558-64.
引用本文的文献
1
Viral Vector-Based Cancer Vaccines.基于病毒载体的癌症疫苗
Methods Mol Biol. 2025;2926:101-127. doi: 10.1007/978-1-0716-4542-0_9.
2
Progression of oncolytic virus in liver cancer treatment.溶瘤病毒在肝癌治疗中的进展。
Front Oncol. 2024 Sep 26;14:1446085. doi: 10.3389/fonc.2024.1446085. eCollection 2024.
3
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.基于病毒载体和病毒样颗粒的传染病疫苗：综述。
Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15.
4
Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.疫苗递送系统与给药途径：提高免疫效力的先进生物技术
Vaccine X. 2024 May 24;19:100500. doi: 10.1016/j.jvacx.2024.100500. eCollection 2024 Aug.
5
Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers.靶向树突状细胞的病毒样颗粒作为有效的mRNA疫苗载体。
Nat Biomed Eng. 2025 Feb;9(2):185-200. doi: 10.1038/s41551-024-01208-4. Epub 2024 May 7.
6
Integrase Defective Lentiviral Vector Promoter Impacts Transgene Expression in Target Cells and Magnitude of Vector-Induced Immune Responses.整合酶缺陷型慢病毒载体启动子影响靶细胞中转基因的表达和载体诱导的免疫反应的程度。
Viruses. 2023 Nov 14;15(11):2255. doi: 10.3390/v15112255.
7
Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.作为针对传染病的疫苗平台的慢病毒载体
Pharmaceutics. 2023 Mar 5;15(3):846. doi: 10.3390/pharmaceutics15030846.
8
A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4 T-cell immunity.一种表达树突状细胞靶向多聚体的慢病毒载体诱导黏膜抗分枝杆菌 CD4 T 细胞免疫。
Mucosal Immunol. 2022 Jun;15(6):1389-1404. doi: 10.1038/s41385-022-00566-z. Epub 2022 Sep 14.
9
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
10
Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.用于预防病毒感染的纳米疫苗递送方法及先进递送系统：从研发到临床应用
Pharmaceutics. 2021 Dec 5;13(12):2091. doi: 10.3390/pharmaceutics13122091.
本文引用的文献
1
Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity.整合缺陷型慢病毒载体靶向树突状细胞的疫苗可诱导强烈的抗原特异性免疫。
Vaccine. 2010 Sep 24;28(41):6675-83. doi: 10.1016/j.vaccine.2010.08.012. Epub 2010 Aug 13.
2
Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice.基于非整合慢病毒载体的疫苗可有效诱导小鼠产生功能性和持久性的CD8+ T细胞应答。
J Biomed Biotechnol. 2010;2010:534501. doi: 10.1155/2010/534501. Epub 2010 May 19.
3
Viral vaccines and CTL response.病毒疫苗与细胞毒性T淋巴细胞反应
J Biomed Biotechnol. 2010;2010:141657. doi: 10.1155/2010/141657. Epub 2010 Mar 31.
4
The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors.皮肤来源树突状细胞在慢病毒载体免疫后 CD8+T 细胞启动中的作用。
J Immunol. 2010 May 1;184(9):4889-97. doi: 10.4049/jimmunol.0903062. Epub 2010 Mar 31.
5
Toward integrase defective lentiviral vectors for genetic immunization.用于基因免疫的整合酶缺陷型慢病毒载体研究
Curr HIV Res. 2010 Jun;8(4):274-81. doi: 10.2174/157016210791208622.
6
HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.HIV-1 慢病毒载体的免疫原性是由 Toll 样受体 3（TLR3）和 TLR7 介导的。
J Virol. 2010 Jun;84(11):5627-36. doi: 10.1128/JVI.00014-10. Epub 2010 Mar 17.
7
Integrase defective, nonintegrating lentiviral vectors.整合酶缺陷型、非整合型慢病毒载体。
Methods Mol Biol. 2010;614:101-10. doi: 10.1007/978-1-60761-533-0_6.
8
Lentiviral vectors for immunization: an inflammatory field.慢病毒载体用于免疫接种：一个炎症领域。
Expert Rev Vaccines. 2010 Mar;9(3):309-21. doi: 10.1586/erv.10.9.
9
Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells.整合酶缺陷型慢病毒载体转导人抗原呈递细胞可实现初始抗原特异性 CD8(+) T 细胞的功能扩增。
Hum Gene Ther. 2010 Aug;21(8):1029-35. doi: 10.1089/hum.2009.200.
10
Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.靶向人端粒酶逆转录酶的重组慢病毒载体在体内能有效刺激抗肿瘤 CD8 T 细胞免疫。
Blood. 2010 Apr 15;115(15):3025-32. doi: 10.1182/blood-2009-11-253641. Epub 2010 Feb 3.
Zotero 插件